ELAVL1 and cancer: Numerous studies demonstrated HuR overexpression and cytoplasmic delocalization in several cancers, including breast cancer, lung adenocarcinoma, ovarian cancer, laryngeal squamous cell cancer and colon cancer7,12, which are often associated with cancer progression and worst prognosis13–16.